

The MOXIe Study

A study of omaveloxolone (RTA 408) in Friedreich's ataxia

MOXIe is a double blind, placebo-controlled, multi-center Phase 2 study of the safety and efficacy of omaveloxolone (RTA 408) in Friedreich's ataxia

About the Study



Treatment: Omaveloxolone or placebo capsules taken by mouth once daily



Approximately 8 visits over 16 weeks



Primary endpoint: Change in peak workload, measured on a recumbent bicycle



Cost of travel may be reimbursed

Criteria for Participation



Between ages 16 and 40



Genetically confirmed Friedreich's ataxia



Willing to discontinue taking some medications




Not pregnant, planning a pregnancy, or breastfeeding

Recruiting Study Center Locations

United States

Europe

Australia



Los Angeles, California: UCLA
Susan Perlman, MD

Gainesville, Florida: University of Florida
S.H. Subramony, MD

Tampa, Florida: University of South Florida
Theresa Zesiewicz, MD

Atlanta, Georgia: Emory University Hospital
George Wilmot, MD

Columbus, Ohio: Ohio State University
Chad Hoyle, MD

Philadelphia, Pennsylvania: CHOP
David Lynch, MD

Innsbruck, Austria: Medical University Innsbruck
Sylvia Boesch, MD

Parkville, Victoria, Australia: Murdoch Children's
Research Institute
Martin Delatycki, MD



Contact information for participating study centers can be found on the clinicaltrials.gov listing



Go to www.clinicaltrials.gov/ct2/show/NCT02255435 for more information

Version 1; September 2016